Explore the current issue of The New England Journal of Medicine (Vol. 395 No. 1).
The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609, 1 request retraction of the article because, according ...
Health care reform in the United States is headed backward. It is uncertain which parts of the Affordable Care Act will survive past 2017 and what will follow it. What is certain is that Obamacare as ...
To the Editor: At the time of the publication of the first PREDIMED (Prevención con Dieta Mediterránea) trial results in 2013, 1 the relative reduction of 30% in the risk of cardiovascular events ...
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight ...
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, ...
Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.
A 56-year-old woman was hospitalized with gait instability. Eight weeks earlier, she had noticed ascending symmetric sensations of painful “pins and needles” that had begun in her feet; she later ...
In this open-label, phase 3 trial, patients with stage IB to IIIA resectable NSCLC were randomly assigned to receive nivolumab plus chemotherapy or chemotherapy alone for three cycles, followed by ...
Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...
Previous analyses of mortality data from the Centers for Disease Control and Prevention (CDC) showed that the leading cause of death among children and adolescents (defined as persons 1 to 19 years of ...
Explore this issue of The New England Journal of Medicine (Vol. 386 No. 3).
一些您可能无法访问的结果已被隐去。
显示无法访问的结果